<?xml version='1.0' encoding='utf-8'?>
<document id="18786302"><sentence text="Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel."><entity charOffset="10-20" id="DDI-PubMed.18786302.s1.e0" text="ranitidine" /><entity charOffset="69-78" id="DDI-PubMed.18786302.s1.e1" text="prasugrel" /><entity charOffset="83-94" id="DDI-PubMed.18786302.s1.e2" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.18786302.s1.e0" e2="DDI-PubMed.18786302.s1.e0" /><pair ddi="false" e1="DDI-PubMed.18786302.s1.e0" e2="DDI-PubMed.18786302.s1.e1" /><pair ddi="false" e1="DDI-PubMed.18786302.s1.e0" e2="DDI-PubMed.18786302.s1.e2" /><pair ddi="false" e1="DDI-PubMed.18786302.s1.e1" e2="DDI-PubMed.18786302.s1.e1" /><pair ddi="false" e1="DDI-PubMed.18786302.s1.e1" e2="DDI-PubMed.18786302.s1.e2" /></sentence><sentence text="Clopidogrel is an oral thienopyridine antiplatelet agent indicated for the treatment of atherothrombotic events in patients with acute coronary syndrome (ACS)"><entity charOffset="0-11" id="DDI-PubMed.18786302.s2.e0" text="Clopidogrel" /><entity charOffset="23-37" id="DDI-PubMed.18786302.s2.e1" text="thienopyridine" /><pair ddi="false" e1="DDI-PubMed.18786302.s2.e0" e2="DDI-PubMed.18786302.s2.e0" /><pair ddi="false" e1="DDI-PubMed.18786302.s2.e0" e2="DDI-PubMed.18786302.s2.e1" /></sentence><sentence text=" Prasugrel, a novel oral thienopyridine, is under investigation for the reduction of atherothrombotic events in patients with ACS undergoing percutaneous coronary intervention"><entity charOffset="1-10" id="DDI-PubMed.18786302.s3.e0" text="Prasugrel" /><entity charOffset="25-39" id="DDI-PubMed.18786302.s3.e1" text="thienopyridine" /><pair ddi="false" e1="DDI-PubMed.18786302.s3.e0" e2="DDI-PubMed.18786302.s3.e0" /><pair ddi="false" e1="DDI-PubMed.18786302.s3.e0" e2="DDI-PubMed.18786302.s3.e1" /></sentence><sentence text=" Prasugrel's solubility decreases with increasing pH, suggesting that concomitantly-administered medications that increase gastric pH may lower the rate and/or extent of prasugrel absorption"><entity charOffset="170-179" id="DDI-PubMed.18786302.s4.e0" text="prasugrel" /></sentence><sentence text=" This study evaluated the influence of ranitidine coadministration on the pharmacokinetics and pharmacodynamics of the respective active metabolite of prasugrel and clopidogrel"><entity charOffset="39-49" id="DDI-PubMed.18786302.s5.e0" text="ranitidine" /><entity charOffset="151-160" id="DDI-PubMed.18786302.s5.e1" text="prasugrel" /><entity charOffset="165-176" id="DDI-PubMed.18786302.s5.e2" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.18786302.s5.e0" e2="DDI-PubMed.18786302.s5.e0" /><pair ddi="false" e1="DDI-PubMed.18786302.s5.e0" e2="DDI-PubMed.18786302.s5.e1" /><pair ddi="false" e1="DDI-PubMed.18786302.s5.e0" e2="DDI-PubMed.18786302.s5.e2" /><pair ddi="false" e1="DDI-PubMed.18786302.s5.e1" e2="DDI-PubMed.18786302.s5.e1" /><pair ddi="false" e1="DDI-PubMed.18786302.s5.e1" e2="DDI-PubMed.18786302.s5.e2" /></sentence><sentence text="" /><sentence text="In this open-label, two-period, two-treatment, crossover study, 47 healthy male subjects were randomized to one of two study arms, receiving either prasugrel (60-mg loading dose [LD], 10-mg maintenance dose [MD] for 7 days; n = 23) or clopidogrel (600-mg LD, 75-mg MD for 7 days; n = 24)"><entity charOffset="148-157" id="DDI-PubMed.18786302.s7.e0" text="prasugrel" /><entity charOffset="235-246" id="DDI-PubMed.18786302.s7.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.18786302.s7.e0" e2="DDI-PubMed.18786302.s7.e0" /><pair ddi="false" e1="DDI-PubMed.18786302.s7.e0" e2="DDI-PubMed.18786302.s7.e1" /></sentence><sentence text=" In one treatment period, subjects received prasugrel or clopidogrel alone, and in the alternate period received the same thienopyridine with ranitidine (150 mg twice daily, starting 1 day before the LD)"><entity charOffset="44-53" id="DDI-PubMed.18786302.s8.e0" text="prasugrel" /><entity charOffset="57-68" id="DDI-PubMed.18786302.s8.e1" text="clopidogrel" /><entity charOffset="122-136" id="DDI-PubMed.18786302.s8.e2" text="thienopyridine" /><entity charOffset="142-152" id="DDI-PubMed.18786302.s8.e3" text="ranitidine" /><pair ddi="false" e1="DDI-PubMed.18786302.s8.e0" e2="DDI-PubMed.18786302.s8.e0" /><pair ddi="false" e1="DDI-PubMed.18786302.s8.e0" e2="DDI-PubMed.18786302.s8.e1" /><pair ddi="false" e1="DDI-PubMed.18786302.s8.e0" e2="DDI-PubMed.18786302.s8.e2" /><pair ddi="false" e1="DDI-PubMed.18786302.s8.e0" e2="DDI-PubMed.18786302.s8.e3" /><pair ddi="false" e1="DDI-PubMed.18786302.s8.e1" e2="DDI-PubMed.18786302.s8.e1" /><pair ddi="false" e1="DDI-PubMed.18786302.s8.e1" e2="DDI-PubMed.18786302.s8.e2" /><pair ddi="false" e1="DDI-PubMed.18786302.s8.e1" e2="DDI-PubMed.18786302.s8.e3" /><pair ddi="false" e1="DDI-PubMed.18786302.s8.e2" e2="DDI-PubMed.18786302.s8.e2" /><pair ddi="false" e1="DDI-PubMed.18786302.s8.e2" e2="DDI-PubMed.18786302.s8.e3" /></sentence><sentence text=" Pharmacokinetic parameter estimates (AUC(0-t last), C(max), and t(max)) and inhibition of platelet aggregation (IPA) by light transmission aggregometry were assessed at multiple time points after the LD and final MD" /><sentence text="" /><sentence text="Ranitidine had no clinically significant effect on the area under the plasma-concentration-time curve (AUC) and did not affect the time to C(max) (t(max)) for active metabolites of either prasugrel or clopidogrel"><entity charOffset="0-10" id="DDI-PubMed.18786302.s11.e0" text="Ranitidine" /><entity charOffset="188-197" id="DDI-PubMed.18786302.s11.e1" text="prasugrel" /><entity charOffset="201-212" id="DDI-PubMed.18786302.s11.e2" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.18786302.s11.e0" e2="DDI-PubMed.18786302.s11.e0" /><pair ddi="false" e1="DDI-PubMed.18786302.s11.e0" e2="DDI-PubMed.18786302.s11.e1" /><pair ddi="false" e1="DDI-PubMed.18786302.s11.e0" e2="DDI-PubMed.18786302.s11.e2" /><pair ddi="false" e1="DDI-PubMed.18786302.s11.e1" e2="DDI-PubMed.18786302.s11.e1" /><pair ddi="false" e1="DDI-PubMed.18786302.s11.e1" e2="DDI-PubMed.18786302.s11.e2" /></sentence><sentence text=" It reduced the geometric mean maximum concentrations of active metabolite (C(max)) after a prasugrel and clopidogrel LD by 14% and 10%, respectively, but these differences were not statistically significant"><entity charOffset="92-101" id="DDI-PubMed.18786302.s12.e0" text="prasugrel" /><entity charOffset="106-117" id="DDI-PubMed.18786302.s12.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.18786302.s12.e0" e2="DDI-PubMed.18786302.s12.e0" /><pair ddi="false" e1="DDI-PubMed.18786302.s12.e0" e2="DDI-PubMed.18786302.s12.e1" /></sentence><sentence text=" When coadministered with a 60-mg prasugrel LD, ranitidine did not affect the time to, or magnitude of, peak IPA, but did result in a modest reduction at 0"><entity charOffset="48-58" id="DDI-PubMed.18786302.s13.e0" text="ranitidine" /></sentence><sentence text="5 h from 67" /><sentence text="4 to 55" /><sentence text="1% (p &lt; 0" /><sentence text="001)" /><sentence text=" Ranitidine did not affect prasugrel IPA during MD"><entity charOffset="1-11" id="DDI-PubMed.18786302.s18.e0" text="Ranitidine" /></sentence><sentence text=" For clopidogrel, IPA was not affected by ranitidine"><entity charOffset="5-16" id="DDI-PubMed.18786302.s19.e0" text="clopidogrel" /><entity charOffset="18-21" id="DDI-PubMed.18786302.s19.e1" text="IPA" /><entity charOffset="42-52" id="DDI-PubMed.18786302.s19.e2" text="ranitidine" /><pair ddi="false" e1="DDI-PubMed.18786302.s19.e0" e2="DDI-PubMed.18786302.s19.e0" /><pair ddi="false" e1="DDI-PubMed.18786302.s19.e0" e2="DDI-PubMed.18786302.s19.e1" /><pair ddi="false" e1="DDI-PubMed.18786302.s19.e0" e2="DDI-PubMed.18786302.s19.e2" /><pair ddi="false" e1="DDI-PubMed.18786302.s19.e1" e2="DDI-PubMed.18786302.s19.e1" /><pair ddi="false" e1="DDI-PubMed.18786302.s19.e1" e2="DDI-PubMed.18786302.s19.e2" /></sentence><sentence text=" Prasugrel and clopidogrel were both well-tolerated, with/without ranitidine"><entity charOffset="1-10" id="DDI-PubMed.18786302.s20.e0" text="Prasugrel" /><entity charOffset="15-26" id="DDI-PubMed.18786302.s20.e1" text="clopidogrel" /><entity charOffset="66-76" id="DDI-PubMed.18786302.s20.e2" text="ranitidine" /><pair ddi="false" e1="DDI-PubMed.18786302.s20.e0" e2="DDI-PubMed.18786302.s20.e0" /><pair ddi="false" e1="DDI-PubMed.18786302.s20.e0" e2="DDI-PubMed.18786302.s20.e1" /><pair ddi="false" e1="DDI-PubMed.18786302.s20.e0" e2="DDI-PubMed.18786302.s20.e2" /><pair ddi="false" e1="DDI-PubMed.18786302.s20.e1" e2="DDI-PubMed.18786302.s20.e1" /><pair ddi="false" e1="DDI-PubMed.18786302.s20.e1" e2="DDI-PubMed.18786302.s20.e2" /></sentence><sentence text="" /><sentence text="Results from this study suggest that there is no significant drug-drug interaction between oral ranitidine therapy and concomitantly-administered prasugrel or clopidogrel"><entity charOffset="96-106" id="DDI-PubMed.18786302.s22.e0" text="ranitidine" /><entity charOffset="146-155" id="DDI-PubMed.18786302.s22.e1" text="prasugrel" /><entity charOffset="159-170" id="DDI-PubMed.18786302.s22.e2" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.18786302.s22.e0" e2="DDI-PubMed.18786302.s22.e0" /><pair ddi="false" e1="DDI-PubMed.18786302.s22.e0" e2="DDI-PubMed.18786302.s22.e1" /><pair ddi="false" e1="DDI-PubMed.18786302.s22.e0" e2="DDI-PubMed.18786302.s22.e2" /><pair ddi="false" e1="DDI-PubMed.18786302.s22.e1" e2="DDI-PubMed.18786302.s22.e1" /><pair ddi="false" e1="DDI-PubMed.18786302.s22.e1" e2="DDI-PubMed.18786302.s22.e2" /></sentence><sentence text="" /></document>